ESR1 and triple-negative breast carcinoma: Additionally, a meta-analysis demonstrated that T2DM was associated with an increased risk of both estrogen receptor-positive (ER+) (RR = 1.09, 95% CI: 1.00–1.20) and triple-negative breast cancer (RR = 1.41, 95% CI: 1.01–1.96) [26].